Bio Tech. Stocks to Watch: SQNM, CELG, VRTX, ZLCS, ARIA

Pompano Beach, FL -- (SBWIRE) -- 01/07/2013 -- Csrnewsdaily.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following Tuesday’s Top Gainers:-

Sequenom, Inc. (NASDAQ:SQNM) is currently trading at $4.98, 4.80% lower. Manufactures DNA detection and sequencing equipment. The Company's two business units combine to utilize their MassARRAY system, SNP assay portfolio, disease gene discovery programs and DNA sample repository. Sequenom provides genetic analysis products that translate genomic science into solutions for biomedical research, molecular medicine and agricultural applications.

Can SQNM Continue To Move Higher? Find Out Here

Celgene Corporation (NASDAQ:CELG) is higher 0.76% to $82.71. Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Can CELG Extend Rally? Find Out Here

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is higher 1.70% to $46.63. Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company’s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene.

How Should Investors Trade VRTX Now? Find Out Here

Zalicus Inc (NASDAQ:ZLCS) among the losers and the stock fell 2.53% to $0.797. Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies.

How Should Investors React To ZLCS Now? Find Out Here

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is lower 1.18% to $19.15. ARIAD Pharmaceuticals, Inc. (ARIAD) is biopharmaceutical company. As of December 31, 2011, the Company’s pipeline contains three product candidates: ponatinib, AP26113 and ridaforolimus. It is building a pipeline of product candidates that expand upon treatment options for patients with cancer. Each of its product candidates were discovered internally. It is building a commercial organization to market, distribute and sell its products upon regulatory approval in the United States, Europe and other select markets, worldwide. It has commenced preparations for the commercial launch of ponatinib in the United States and Europe.

How Should Investors React To ARIA Now? Find Out Here

About Csrnewsdaily.com
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.

Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.

Disclaimer
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.

Contact:
Csrnewsdaily.com
info@csrnewsdaily.com